Jamie Kasuboski
Founder at Avilar Therapeutics, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Milind Deshpande | M | 67 |
Avilar Therapeutics, Inc.
 Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau. | 4 years |
| Stephanie Tozzo | M | 62 |
Avilar Therapeutics, Inc.
Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau. | 3 years |
| Daniel Estandian | M | - |
Glyphic Biotechnologies Inc
 Glyphic Biotechnologies Inc Miscellaneous Commercial ServicesCommercial Services Glyphic Biotechnologies Inc is an American biotechnology company that develops a protein sequencing platform to provide researchers with new insights into biology and disease. Glyphic Biotechnologies was founded by Joshua Yang and Daniel Estandian, with Joshua Yang serving as the CEO since incorporation. | - |
| Joshua Yang | M | - |
Glyphic Biotechnologies Inc
Glyphic Biotechnologies Inc Miscellaneous Commercial ServicesCommercial Services Glyphic Biotechnologies Inc is an American biotechnology company that develops a protein sequencing platform to provide researchers with new insights into biology and disease. Glyphic Biotechnologies was founded by Joshua Yang and Daniel Estandian, with Joshua Yang serving as the CEO since incorporation. | 3 years |
| Swetha Murali | F | - |
Omx Ventures LLC
 Omx Ventures LLC Investment ManagersFinance OMX Ventures LLC (OMX Ventures) is a venture capital firm founded in 2020. The firm is headquartered in Lincolnshire, Illinois. | 3 years |
| Robert Bernhard | M | 71 |
University of Notre Dame
| 17 years |
| A. Asher | M | - |
Glyphic Biotechnologies Inc
Glyphic Biotechnologies Inc Miscellaneous Commercial ServicesCommercial Services Glyphic Biotechnologies Inc is an American biotechnology company that develops a protein sequencing platform to provide researchers with new insights into biology and disease. Glyphic Biotechnologies was founded by Joshua Yang and Daniel Estandian, with Joshua Yang serving as the CEO since incorporation. | 3 years |
| Michael Francis Quinlan | M | - |
University of Notre Dame
| 16 years |
| Don N. Kleinmuntz | M | - |
Omx Ventures LLC
Omx Ventures LLC Investment ManagersFinance OMX Ventures LLC (OMX Ventures) is a venture capital firm founded in 2020. The firm is headquartered in Lincolnshire, Illinois. | 3 years |
| Sara Tucker | F | 68 |
University of Notre Dame
| 15 years |
| NATHANIEL BROOKS HORWITZ | M | - |
Avilar Therapeutics, Inc.
Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau. | 5 years |
| Joshua Resnick | M | - |
Avilar Therapeutics, Inc.
Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau. | - |
| Frédéric Sweeney | M | - |
Omx Ventures LLC
Omx Ventures LLC Investment ManagersFinance OMX Ventures LLC (OMX Ventures) is a venture capital firm founded in 2020. The firm is headquartered in Lincolnshire, Illinois. | 2 years |
| Marty Freed | M | - |
Avilar Therapeutics, Inc.
Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau. | - |
| Peter Friedland | M | - |
University of Notre Dame
| 15 years |
| Tess Cameron | F | - |
Avilar Therapeutics, Inc.
Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau. | 4 years |
| Roderick West | M | 55 |
University of Notre Dame
| 15 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Andrew E. Winslow | M | - |
University of Notre Dame
| 4 years |
| Sam Chen | M | - |
University of Notre Dame
| 1 years |
| Erin Hill | F | - |
University of Notre Dame
| 4 years |
| Ryan Euell | M | - |
University of Notre Dame
| 5 years |
| Giorgio Julia | F | - |
University of Notre Dame
| 5 years |
| Alexander Ryan | M | - |
University of Notre Dame
| 4 years |
| Jonathan Michael Koop | M | - |
University of Notre Dame
| 6 years |
| Dan Finan | M | - |
University of Notre Dame
| 5 years |
| Tony J. Schiazza | M | - |
University of Notre Dame
| 4 years |
| Brian Reynolds | M | - |
University of Notre Dame
| 5 years |
| David Sutherland | M | - |
University of Notre Dame
| 7 years |
| Emily Susan Muhleman | F | - |
University of Notre Dame
| 1 years |
| Molly Iarocci | F | - |
University of Notre Dame
| 6 years |
| Conor Kelly | M | - |
University of Notre Dame
| 5 years |
| Sean Colleran | M | - |
University of Notre Dame
| 5 years |
| Amanda Tedesco Leithe | F | - |
University of Notre Dame
| 4 years |
| Brett A. Berceau | M | - |
University of Notre Dame
| 4 years |
| Yang Liu | M | 43 |
University of Notre Dame
| 1 years |
| Matt Libel | M | - |
University of Notre Dame
| 4 years |
| Rob Wahl | M | - |
University of Notre Dame
| 4 years |
| Michael Cochran | M | - |
University of Notre Dame
| 4 years |
| Jose Linardi | M | - |
University of Notre Dame
| 4 years |
| Brendan Barrett | M | 38 |
University of Notre Dame
| 4 years |
| Emma Gergen | F | - |
University of Notre Dame
| 4 years |
| Zach Schneider | M | - |
University of Notre Dame
| 2 years |
| Kevin Kershisnik | M | - |
University of Notre Dame
| 4 years |
| Samuel Reiff | M | - |
University of Notre Dame
| 4 years |
| Carol A. Dixon | F | - |
University of Notre Dame
| 4 years |
| Brian Lasky | M | - |
University of Notre Dame
| 4 years |
| MICHAEL BLUME | M | - |
University of Notre Dame
| 4 years |
| Daniel Gedney | M | - |
University of Notre Dame
| 4 years |
| Matt Woebkenberg | M | - |
University of Notre Dame
| 4 years |
| Eric Robert Turner | M | - |
University of Notre Dame
| 4 years |
| Alan Rambaldini | M | - |
University of Notre Dame
| 2 years |
| Greg Belatti | M | - |
University of Notre Dame
| 4 years |
| Beau Duncan | M | - |
University of Notre Dame
| 4 years |
| Patrick Bernard Donnelly | M | - |
University of Notre Dame
| 4 years |
| Elizabeth Luciano | F | - |
University of Notre Dame
| 4 years |
| Colin Falls | M | - |
University of Notre Dame
| 4 years |
| Steve Roszak | M | - |
University of Notre Dame
| 4 years |
| Charlie Landry | M | - |
University of Notre Dame
| 4 years |
| Thomas Balderston | M | - |
University of Notre Dame
| 4 years |
| Kara Dowley | F | - |
University of Notre Dame
| 4 years |
| David Venker | M | - |
University of Notre Dame
| 4 years |
| Ted Nickels | M | - |
University of Notre Dame
| 4 years |
| Eric Turner | M | - |
University of Notre Dame
| 4 years |
| Crystal Lin | F | - |
University of Notre Dame
| 4 years |
| Lauren Sullivan | F | - |
University of Notre Dame
| 4 years |
| Noreen Anjum Kazi | F | - |
University of Notre Dame
| 2 years |
| Max Pinigin | M | - |
University of Notre Dame
| 2 years |
| Blair M. Brenton | M | - |
University of Notre Dame
| 4 years |
| Patrick Schafer | M | 38 |
University of Notre Dame
| 4 years |
| Kate D. Spitz | F | - |
University of Notre Dame
| 3 years |
| Trent William DeBruin | M | - |
University of Notre Dame
| 4 years |
| Dustin Zhang | M | - |
University of Notre Dame
| 4 years |
| Brian Sefton | M | - |
University of Notre Dame
| 4 years |
| Mike Cikos | M | - |
University of Notre Dame
| 4 years |
| Andrew Eggert | M | - |
University of Notre Dame
| 4 years |
| Santiago Montoya | M | - |
University of Notre Dame
| 4 years |
| Thomas J. Gaul | M | - |
University of Notre Dame
| 4 years |
| Daniel Joseph Fuss | M | - |
University of Notre Dame
| 4 years |
| Michael Amenta | M | - |
University of Notre Dame
| 4 years |
| J. Terrell Siegfried | M | - |
University of Notre Dame
| 3 years |
| Larry Witt | M | - |
University of Notre Dame
| 2 years |
| Matthew J. Pyzyk | M | - |
University of Notre Dame
| 2 years |
| Charlie Spokes | M | - |
University of Notre Dame
| 4 years |
| Andrew Simms | M | - |
University of Notre Dame
| 4 years |
| Eric M. Robinson | M | - |
University of Notre Dame
| 4 years |
| Kathleen Souder | F | - |
University of Notre Dame
| 4 years |
| Nate Burggraf | M | - |
University of Notre Dame
| 4 years |
| Michael Richard Metschl | M | - |
University of Notre Dame
| 4 years |
| Sloan Smith | M | - |
University of Notre Dame
| 4 years |
| Victor Abiamiri | M | - |
University of Notre Dame
| 4 years |
| Tom Mahoney | M | - |
University of Notre Dame
| 4 years |
| Dave Weinstein | M | - |
University of Notre Dame
| 2 years |
| Tim Keebler | M | - |
University of Notre Dame
| 4 years |
| Kevin Archer | M | - |
University of Notre Dame
| 4 years |
| Ryan P. Downie | M | - |
University of Notre Dame
| 4 years |
| Sam J. Beres | M | - |
University of Notre Dame
| 4 years |
| Matt Larew | M | - |
University of Notre Dame
| 4 years |
| Eric Christiansen | M | - |
University of Notre Dame
| 4 years |
| Matthew Puglisi | M | - |
University of Notre Dame
| 4 years |
| David Dragich | M | - |
University of Notre Dame
| 13 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jamie Kasuboski
- Personal Network
